Free Trial

Pliant Therapeutics (PLRX) 10K Form and Latest SEC Filings 2026

Pliant Therapeutics logo
$1.20 +0.02 (+1.26%)
As of 03:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Pliant Therapeutics SEC Filings & Recent Activity

Pliant Therapeutics (NASDAQ:PLRX) has submitted 288+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form ARS submitted on April 22, 2026.

Form 4
PLIANT THERAPEUTICS, INC. Reports Ownership Change on Apr. 17, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Pliant Therapeutics Files Current Report on Apr. 17, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Pliant Therapeutics SEC Filing History

Browse Pliant Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/22/2026 3:30 PM
Pliant Therapeutics (1746473) Filer
Form DEF 14A
04/22/2026 3:31 PM
Pliant Therapeutics (1746473) Filer
Form DEFA14A
04/22/2026 3:33 PM
Pliant Therapeutics (1746473) Filer
Form ARS
04/17/2026 3:42 PM
Cheung Lily (1962207) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 3:42 PM
Coulie Bernard (1808895) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 3:42 PM
Cummings Keith Lamont (1809204) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 3:42 PM
Kuo Minnie (2101360) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 3:30 PM
Pliant Therapeutics (1746473) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/06/2026 11:15 PM
Pliant Therapeutics (1746473) Filer
Form EFFECT
03/11/2026 3:32 PM
Pliant Therapeutics (1746473) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/17/2026 3:29 PM
Pliant Therapeutics (1746473) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G/A
02/09/2026 5:13 PM
CITADEL ADVISORS LLC (1423053) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G
01/30/2026 6:11 PM
CITADEL ADVISORS LLC (1423053) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G
01/26/2026 3:36 PM
Coulie Bernard (1808895) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:36 PM
Cheung Lily (1962207) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:36 PM
Kuo Minnie (2101360) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 3:36 PM
Cummings Keith Lamont (1809204) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 8:38 PM
Kuo Minnie (2101360) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 8:38 PM
Coulie Bernard (1808895) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 8:38 PM
Cheung Lily (1962207) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 8:46 PM
Cummings Keith Lamont (1809204) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 6:02 PM
CITADEL ADVISORS LLC (1423053) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G
12/22/2025 4:02 PM
Kuo Minnie (2101360) Reporting
Pliant Therapeutics (1746473) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/16/2025 4:05 PM
Pliant Therapeutics (1746473) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/08/2025 3:41 PM
Pliant Therapeutics (1746473) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 7:22 AM
Deep Track Capital, LP (1856083) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G/A
11/06/2025 3:09 PM
Pliant Therapeutics (1746473) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2025 3:32 PM
Pliant Therapeutics (1746473) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/04/2025 4:13 PM
Pliant Therapeutics (1746473) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
08/14/2025 7:49 AM
Deep Track Capital, LP (1856083) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G/A
08/06/2025 1:12 PM
MORGAN STANLEY (895421) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G
07/17/2025 7:12 PM
BlackRock, Inc. (2012383) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G/A
06/09/2025 7:42 PM
CROWELL GAYLE A (1250893) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:43 PM
Huh Hoyoung (1401267) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:43 PM
Pliant Therapeutics (1746473) Issuer
PYOTT DAVID E I (1051578) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:43 PM
Cline Darren S (1633639) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:43 PM
Krognes Steve E. (1666236) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:44 PM
Curnutte John T (1574589) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:44 PM
MCCOURT Thomas A (1478448) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:44 PM
Knobil Katharine (1768011) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:44 PM
Bruhn Suzanne Louise (1517790) Reporting
Pliant Therapeutics (1746473) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 4:29 PM
Pliant Therapeutics (1746473) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025 3:39 PM
Paradigm Biocapital Advisors LP (1855655) Filed by
Pliant Therapeutics (1746473) Subject
Form SCHEDULE 13G/A
05/14/2025 9:45 AM
Pliant Therapeutics (1746473) Subject
PRICE T ROWE ASSOCIATES INC /MD/ (80255) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Pliant Therapeutics SEC Filings - Frequently Asked Questions

Pliant Therapeutics (PLRX) has submitted 288+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Pliant Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form ARS submitted on April 22, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:PLRX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners